Clinical Trials
9 trialsNCT04188405 2026-05-22
Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT00042003 2024-08-02
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
Astex Pharmaceuticals, Inc.
Phase 2 Completed
NCT05524857 2024-04-23
Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)
Columbia University
Phase 1 Terminated
NCT01498445 2020-10-22
An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT00002831 2018-10-26
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00275080 2014-08-27
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00002980 2013-02-15
Decitabine in Treating Patients With Melanoma or Other Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00054431 2013-01-23
Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00002832 2012-07-30
Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed